Opioid extended-release tablets with improved tamper-resistant properties

Bibliography

• Substance Abuse and Mental Health Services Administration. Results from the 2010 national survey on drug use and health: summary of national findings. Substance Abuse and Mental Health Services Administration; Rockville, MD: 2011. Report No.: NSDUH Series H-41, HHS Publication No. (SMA) 11-4658
   Google Scholar
• Dhalla IA, Mamdani MM, Sivilotti ML, Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone. CMAJ 2009;181:891-6
   PubMed Web of Science ®Google Scholar
• Butler SF, Black RA, Cassidy TA, Abuse risks and routes of administration of different prescription opioid compounds and formulations. Harm Reduct J 2011;8:29
   PubMed Web of Science ®Google Scholar
• Osgood ED, Eaton TA, Trudeau JJ, Katz NP. A brief survey to characterize oxycodone abuse patterns in adolescents enrolled in two substance abuse recovery high schools. Am J Drug Alcohol Abuse 2012;38:166-70
   PubMed Web of Science ®Google Scholar
• EMBEDA® (morphine sulfate and naltrexone hydrochloride). Full Prescribing Information. King Pharmaceuticals; Bristol, TN: 2009
   Google Scholar
• OxyContin® (oxycodone HCl controlled-release tablets). Full Prescribing Information. Purdue Pharma L.P.; Stamford, CT: 2010
   Google Scholar
• OXECTA® (oxycodone HCl, USP). Full Prescribing Information. King Pharmaceuticals; Bristol, TN: 2011
   Google Scholar
• NUCYNTA® ER (tapentadol). Full Prescribing Information. Janssen Pharmaceuticals, Inc., Titusville, NJ: 2011
   Google Scholar
• OPANA® ER (oxymorphone hydrochloride). Full Prescribing Information. Endo Pharmaceuticals; Chadds Ford, PA, USA: 2012
   Google Scholar
• Bartholomaus J, Geissler A, Bertram U, Griessmann K. Tamper-resistant dosage form for oxidation-sensitive opioids. WO2011009603; 2011
   Google Scholar
• Katz N. Abuse-deterrent opioid formulations: are they a pipe dream? Curr Rheumatol Rep 2008;10:11-18
   PubMedGoogle Scholar
• McKenna WH, Mannion RO, O'Donnell EP, Huang HH. Tamper resistant dosage forms. US20090081290A1; 2009
   Google Scholar
• Mastropietro DJ, Omidian H. Current approaches in tamper-resistant and abuse-deterrent formulations. Drug Dev Ind Pharm 2012. [Epub ahead of print]
   Web of Science ®Google Scholar
• Dowwolff Cellulosics. POLYOX physical properties. 2011. Available from: http://dowwolff.custhelp.com/app/answers/detail/a_id/1377/∼/polyox-physical-properties [Last accessed January 24 2012]
   Google Scholar
• Bartholomaus J, Kugelmann H, Arkenau-Maric E. Form of administration secured against misuse. EP1658055B1; 2007
   Google Scholar
• Bartholomaus J, Arkenau-Maric E. Method for the production of an administration form which is secured against misuse. EP1699440B1; 2009
   Google Scholar
• Bartholomaus J, Arkenau-Maric E. Method for the production of an abuse-proof, solid form of administration. EP1740156B1; 2011
   Google Scholar
• Bartholomaus J, Kugelmann H, Arkenau-Maric E. Dosage form that is safeguarded from abuse. EP1658054B1; 2007
   Google Scholar
• Arkenau-Maric E, Bartholomaus J, Schateikis D. Form of administration secured against misuse. WO20088145334; 2008
   Google Scholar
• International Conference on Harmonisation. Stability Testing: Photostability Testing of New Drug Substances and Products (Q1B): International Conference on Harmonisation; 1996. Report No.: CPMP/ICH/279/95
   Google Scholar
• International Conference on Harmonisation. Stability Testing for New Dosage Forms (Q1C): International Conference on Harmonisation; 1996. Report No.: CPMP/ICH/280/95
   Google Scholar
• International Conference on Harmonisation. Bracketing and Matrixing Designs for Stability Testing of New Drug Substances and Products (Q1D): International Conference on Harmonisation; 2002. Report No.: CPMP/ICH/4104/00
   Google Scholar
• International Conference on Harmonisation. Stability Testing of New Drug Substances and Research (Q1A): International Conference on Harmonisation; 2003. Report No.: CPMP/ICH/2736/99
   Google Scholar
• International Conference on Harmonisation. Evaulation of Stability Data (Q1E): International Conference on Harmonisation; 2003. Report No.: CPMP/ICH/420/02
   Google Scholar
• Benedek IH, Jobes J, Xiang Q, Fiske WD. Bioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended release. Drug Des Devel Ther 2011;5:455-63
   PubMed Web of Science ®Google Scholar
• Butler SF, Black R, Grimes Serrano JM, Estimating attractiveness for abuse of a not-yet-marketed “abuse-deterrent” prescription opioid formulation. Pain Med 2010;11:81-91
   PubMed Web of Science ®Google Scholar
• Sokolowska M, Comer SD, Sullivan MA, Ashworth JB. Can increasing mechanical stability of controlled release tablets decrease drug preference and the street value of the drug? [abstract PM 387]. 13th Congress of the International Association for the Study of Pain; 2010 August 29-September 2; Montreal, QC, Canada. Available from: http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=61f3d88d-52e8-404a-8e7a-ef29e654ada1&cKey=76cd0256-aba8-467c-a7ec-6b1d02acec8a&mKey=%7B3F846F23-E219-40A0-B790-DBC3F75684FD%7D [Last accessed 23 May 2012]
   Google Scholar
• Vosburg SK, Jones JD, Manubay JM, Assessment of a formulation designed to be crush-resistant in prescription opioid abusers. Drug Alcohol Depend 2012; In press
   PubMed Web of Science ®Google Scholar
• Black R, Coplan P, Cassidy T, Effects of reformulated OxyContin® among patients assessed for substance abuse treatment in the NAVIPPRO sentinal surveillance network. J Pain 2012;13:S58
   PubMed Web of Science ®Google Scholar
• Mitchell JF. Oral dosage forms that should not be crushed. 2011. Available from: http://www.ismp.org/Tools/DoNotCrush.pdf [Last accessed 24 January 2012]
   Google Scholar